178 related articles for article (PubMed ID: 10849448)
21. The SH2-containing adapter protein GRB10 interacts with BCR-ABL.
Bai RY; Jahn T; Schrem S; Munzert G; Weidner KM; Wang JY; Duyster J
Oncogene; 1998 Aug; 17(8):941-8. PubMed ID: 9747873
[TBL] [Abstract][Full Text] [Related]
22. Mutant forms of growth factor-binding protein-2 reverse BCR-ABL-induced transformation.
Gishizky ML; Cortez D; Pendergast AM
Proc Natl Acad Sci U S A; 1995 Nov; 92(24):10889-93. PubMed ID: 7479904
[TBL] [Abstract][Full Text] [Related]
23. The Ras GTPase-activating protein (GAP) is an SH3 domain-binding protein and substrate for the Src-related tyrosine kinase, Hck.
Briggs SD; Bryant SS; Jove R; Sanderson SD; Smithgall TE
J Biol Chem; 1995 Jun; 270(24):14718-24. PubMed ID: 7782336
[TBL] [Abstract][Full Text] [Related]
24. Polyomavirus middle-T antigen associates with the kinase domain of Src-related tyrosine kinases.
Dunant NM; Senften M; Ballmer-Hofer K
J Virol; 1996 Mar; 70(3):1323-30. PubMed ID: 8627648
[TBL] [Abstract][Full Text] [Related]
25. Association of Bcr-Abl with the proto-oncogene Vav is implicated in activation of the Rac-1 pathway.
Bassermann F; Jahn T; Miething C; Seipel P; Bai RY; Coutinho S; Tybulewicz VL; Peschel C; Duyster J
J Biol Chem; 2002 Apr; 277(14):12437-45. PubMed ID: 11790798
[TBL] [Abstract][Full Text] [Related]
26. PI 3-kinase activation in BCR/abl-transformed hematopoietic cells does not require interaction of p85 SH2 domains with p210 BCR/abl.
Jain SK; Susa M; Keeler ML; Carlesso N; Druker B; Varticovski L
Blood; 1996 Sep; 88(5):1542-50. PubMed ID: 8781408
[TBL] [Abstract][Full Text] [Related]
27. Global phosphoproteomics reveals crosstalk between Bcr-Abl and negative feedback mechanisms controlling Src signaling.
Rubbi L; Titz B; Brown L; Galvan E; Komisopoulou E; Chen SS; Low T; Tahmasian M; Skaggs B; Müschen M; Pellegrini M; Graeber TG
Sci Signal; 2011 Mar; 4(166):ra18. PubMed ID: 21447799
[TBL] [Abstract][Full Text] [Related]
28. BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias.
Muller AJ; Young JC; Pendergast AM; Pondel M; Landau NR; Littman DR; Witte ON
Mol Cell Biol; 1991 Apr; 11(4):1785-92. PubMed ID: 2005881
[TBL] [Abstract][Full Text] [Related]
29. Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis.
Nieborowska-Skorska M; Wasik MA; Slupianek A; Salomoni P; Kitamura T; Calabretta B; Skorski T
J Exp Med; 1999 Apr; 189(8):1229-42. PubMed ID: 10209040
[TBL] [Abstract][Full Text] [Related]
30. Phosphorylation-dependent interactions between ADAM15 cytoplasmic domain and Src family protein-tyrosine kinases.
Poghosyan Z; Robbins SM; Houslay MD; Webster A; Murphy G; Edwards DR
J Biol Chem; 2002 Feb; 277(7):4999-5007. PubMed ID: 11741929
[TBL] [Abstract][Full Text] [Related]
31. Affinity of Src family kinase SH3 domains for HIV Nef in vitro does not predict kinase activation by Nef in vivo.
Briggs SD; Lerner EC; Smithgall TE
Biochemistry; 2000 Jan; 39(3):489-95. PubMed ID: 10642173
[TBL] [Abstract][Full Text] [Related]
32. The BCR-ABL oncogene requires both kinase activity and src-homology 2 domain to induce cytokine secretion.
Anderson SM; Mladenovic J
Blood; 1996 Jan; 87(1):238-44. PubMed ID: 8547647
[TBL] [Abstract][Full Text] [Related]
33. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia.
Shuai K; Halpern J; ten Hoeve J; Rao X; Sawyers CL
Oncogene; 1996 Jul; 13(2):247-54. PubMed ID: 8710363
[TBL] [Abstract][Full Text] [Related]
34. SH3-mediated Hck tyrosine kinase activation and fibroblast transformation by the Nef protein of HIV-1.
Briggs SD; Sharkey M; Stevenson M; Smithgall TE
J Biol Chem; 1997 Jul; 272(29):17899-902. PubMed ID: 9218412
[TBL] [Abstract][Full Text] [Related]
35. The human immunodeficiency virus type 1 Nef protein binds the Src-related tyrosine kinase Lck SH2 domain through a novel phosphotyrosine independent mechanism.
Dutartre H; Harris M; Olive D; Collette Y
Virology; 1998 Aug; 247(2):200-11. PubMed ID: 9705913
[TBL] [Abstract][Full Text] [Related]
36. Biochemical properties of the Cdc42-associated tyrosine kinase ACK1. Substrate specificity, authphosphorylation, and interaction with Hck.
Yokoyama N; Miller WT
J Biol Chem; 2003 Nov; 278(48):47713-23. PubMed ID: 14506255
[TBL] [Abstract][Full Text] [Related]
37. The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3' kinase pathway.
Sattler M; Salgia R; Okuda K; Uemura N; Durstin MA; Pisick E; Xu G; Li JL; Prasad KV; Griffin JD
Oncogene; 1996 Feb; 12(4):839-46. PubMed ID: 8632906
[TBL] [Abstract][Full Text] [Related]
38. Regulation of p73 by Hck through kinase-dependent and independent mechanisms.
Paliwal P; Radha V; Swarup G
BMC Mol Biol; 2007 May; 8():45. PubMed ID: 17535448
[TBL] [Abstract][Full Text] [Related]
39. Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line.
Matulonis U; Salgia R; Okuda K; Druker B; Griffin JD
Exp Hematol; 1993 Oct; 21(11):1460-6. PubMed ID: 8405226
[TBL] [Abstract][Full Text] [Related]
40. Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms.
Dai Y; Rahmani M; Pei XY; Dent P; Grant S
Blood; 2004 Jul; 104(2):509-18. PubMed ID: 15039284
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
